Since the discovery of the v-src and c-src genes and their products, much progress has been made in the elucidation of the structure, regulation, localization, and function of the Src protein. Src is a non-receptor protein tyrosine kinase that transduces signals that are involved in the control of a variety of cellular processes such as proliferation, dierentiation, motility, and adhesion. Src is normally maintained in an inactive state, but can be activated transiently during cellular events such as mitosis, or constitutively by abnormal events such as mutation (i.e. v-Src and some human cancers). Activation of Src occurs as a result of disruption of the negative regulatory processes that normally suppress Src activity, and understanding the various mechanisms behind Src activation has been a target of intense study. Src associates with cellular membranes, in particular the plasma membrane, and endosomal membranes. Studies indicate that the dierent subcellular localizations of Src could be important for the regulation of speci®c cellular processes such as mitogenesis, cytoskeletal organization, and/or membrane tracking. This review will discuss the history behind the discovery and initial characterization of Src and the regulatory mechanisms of Src activation, in particular, regulation by modi®cation of the carboxyterminal regulatory tyrosine by phosphatases and kinases. Its focus will then turn to the dierent subcellular localizations of Src and the possible roles of nuclear and perinuclear targets of Src. Finally, a brief section will review some of our present knowledge regarding Src involvement in human cancers. Oncogene (2000) 19, 5620 ± 5635.
Introduction
The cytoplasmic tyrosine kinase Src has been the subject of widespread interest for several years, either in the form of v-Src, an activated form encoded by the v-src transforming gene of Rous Sarcoma virus (RSV), or in the form of c-Src, encoded by the c-src gene of multicellular organisms. Important breakthroughs in this ®eld arose from studies on Rous sarcoma virus, a chicken tumor virus discovered in 1910 by Peyton Rous (Rous, 1910) , which became the subject of intensive investigation in the 1960's and 1970's. Although RSV possessed a small genome encoding only a few gene products, it was capable of causing tumors in chickens and rapidly transforming cells in culture with high eciency. The development of the focus assay by Temin and Rubin (Temin and Rubin, 1958) , and advances made in the understanding of biological properties and host range speci®city of avian tumor virus in cell culture by the laboratories of P Vogt, H Hanafusa and others (Hanafusa, 1965; Vogt and Ishizaki, 1966) established RSV as a highly favorable model tumor virus system. A series of elegant pioneering genetic and biochemical studies in the late 1960's and 1970's by several laboratories ushered in a period of rapid and exciting progress in RSV and Src research. These studies led to the elucidation of RSV gene functions and genome structure (Robinson et al., 1967; Wang et al., 1975a,b; Joho et al., 1975) , identi®cation of v-src as the only RSV gene that was required for triggering cell transformation (Martin et al., 1971; Vogt, 1971; Lai et al., 1973; Wang et al., 1975a) and the discovery that the v-src gene product pp60 v-src , or v-Src, was a phosphoprotein with an apparent molecular mass of 60 kDa (Brugge and Erikson, 1977; Purchio et al., 1978) . Shortly thereafter, it was found ®rst that the vSrc protein possessed an intrinsic protein kinase activity (Collett and Erikson, 1978; Levinson et al., 1978) , followed by the discovery that Src was a protein kinase that phosphorylated tyrosine residues (Hunter and Sefton, 1980; Collett et al., 1980) . In contrast, most other protein kinases at that time were known to phosphorylate only serine or threonine residues. In addition, research on RSV, as well as independent studies on the murine leukemia retrovirus MLV, led to the co-discovery of reverse transcriptase (RNA-dependent DNA polymerase) (Temin and Mizutani, 1970; Baltimore, 1970) .
The discovery of reverse transcriptase not only greatly facilitated the development of the modern era of molecular cloning, but also was instrumental in the synthesis and puri®cation of a v-src speci®c cDNA, which was an essential reagent in the discovery of c-src, the cellular homologue and progenitor of v-src, in normal cellular DNA (Stehelin et al., 1976a,b) . The discovery of c-src, which was the ®rst cellular homologue or protooncogene form of a viral oncogene to be uncovered, stimulated the search for, and discovery of, numerous other cellular proto-oncogenes, which has ultimately led to important knowledge regarding these proto-oncogenes and the signaling pathways that they are involved in.
The discovery of the cellular form of Src kinase, pp60 c-src , or c-Src, in uninfected cells (Collett et al., 1979; Oppermann et al., 1979) , followed by molecular cloning and sequencing of the chicken c-src gene (Parker et al., 1981; Shalloway et al., 1981; Takeya et al., 1982) and the RSV v-src gene (Czernilofsky et al., 1980 (Czernilofsky et al., , 1983 led to the ®nding that the cellular c-Src and RSV v-Src proteins were closely related but that they diered substantially at their carboxy-termini (Takeya and Hanafusa, 1983) . In particular, although c-Src and v-Src exhibited several single amino acid dierences, the most striking dierence was the replacement of the carboxy-terminal 19 amino acids of chicken c-Src by 12 completely dierent amino acids in RSV v-Src. Therefore v-Src, which contained 526 amino acids was a truncated and altered form of chicken c-Src which contained 533 amino acids (see Figure 1 ) (Takeya and Hanafusa, 1983) . This basic structural dierence between v-Src and c-Src was also con®rmed by the sequencing of cloned forms of the human c-src gene (Anderson et al., 1985; Tanaka et al., 1987) . c-Src also diered from v-Src in two important respects: (1) The protein tyrosine kinase activity of cSrc in immunoprecipitates was generally lower than that of v-Src (Iba et al., 1984; Coussens et al., 1985; Tanaka and Fujita, 1986) and (2) c-Src, unlike v-Src, did not cause cell transformation as measured by focus formation in chicken embryo ®broblast cells under conditions of moderate overexpression (Iba et al., 1984; Shalloway et al., 1984; Tanaka and Fujita, 1986) . Experiments using chimeric forms of c-Src and v-Src indicated that replacement of the c-Src carboxyterminus with that of v-Src could confer high kinase activity and transforming activity upon the resulting Src chimera (Iba et al., 1984; Tanaka and Fujita, 1986) . These experiments, and others, suggested that the carboxy-terminal regions of c-Src and v-Src played important roles in regulating Src activity, as discussed further in the next section.
Src regulation
With the discovery that v-Src is a constitutively activated form of c-Src, and that v-Src is capable of eliciting many dramatic biological responses within cells, including cellular transformation, investigators proceeded to search for situations where c-Src becomes activated, and then to characterize the molecular mechanisms behind Src activation. The results of these studies revealed that there are many dierent processes that can alter c-Src activity, and ultimately, the signals generated downstream of Src. In many cases, these or similar mechanisms of regulation are applicable to the multiple members of the Src family of tyrosine kinases, which include Src, Fyn, Yes, Lck, Hck, Blk, Fgr, Lyn, and Yrk. For the purposes of this section of the review, we will brie¯y discuss some of these activation/ inactivation processes, with a focus upon the kinases and phosphatases which directly alter the phosphorylation status of a critical carboxy-terminal negative regulatory tyrosine residue of c-Src, Tyr(527/530), and how these proteins are regulated.
Regulation of c-Src by phosphorylation
An important mechanism for regulation of c-Src tyrosine kinase activity is through control of its phosphorylation status. There are two major phosphorylation sites present on human c-Src (see Figure  1 ), Tyr419 (Tyr416 in chicken) and Tyr530 (Tyr527 in chicken). To avoid confusion when referring to the phosphorylation sites in the context of these two dierent species, we will refer to the positive regulatory autophosphorylation site as Tyr(416/419) and the negative regulatory carboxy-terminal phosphorylation site as Tyr(527/530) throughout this review.
A major phosphorylation site that appears critical for regulation of c-Src tyrosine kinase activity is the carboxy-terminal tyrosine Tyr(527/530) (Cooper et al., 1986; Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987) , that is not present in v-Src. Biochemical data has been obtained supporting the hypothesis that the carboxy-terminal tyrosine residue, when phosphorylated, interacts with the SH2 domain of Src (Roussel et al., 1991; Liu et al., 1993; Bibbins et al., 1993) . This interaction results in the suppression of the tyrosine kinase activity of c-Src. More recently, structural data from X-ray crystallography of Src (Xu et al., 1997) and other Src-family members (Yamaguchi and Hendrickson, 1996; Sicheri et al., 1997) has supported the presence of an intramolecular interaction between the SH2 domain and the phosphorylated carboxy-terminal tyrosine. In addition, other intramolecular interactions, in particular between the SH3 domain and the SH2-kinase linker, also appear to play a role in suppressing c-Src tyrosine kinase activity (see Figure 2) . Dephosphorylation of Tyr(527/530) relieves the intramolecular inhibition of c-Src kinase activity, and c-Src becomes active. Several tyrosine kinases and PTPs (protein tyrosine phosphatases) have been implicated in the control of the phosphorylation status of this key residue, and will be discussed in detail in subsequent sections of this review.
A second major phosphorylation site, Tyr(416/419), is present within the`activation loop', a sequence which is conserved amongst many tyrosine kinases and Figure 1 Src is the founding member of the Src family of structurally-related protein tyrosine kinases. Src and Src-family members possess (starting on the left, at the amino-terminus) a domain that undergoes fatty acid modi®cation (myristoylation in the case of Src; Myr), a unique region, an SH3 domain, an SH2 domain, the SH2-kinase linker, a kinase domain, and a carboxyterminal regulatory domain. Chicken Src contains 533 amino acids, but human Src contains a total of three additional amino acids inserted at two sites within the unique domain resulting in a protein that is 536 amino acids. Human Src possesses a positiveregulatory autophosphorylation site at Tyr419 (Tyr416 in chicken Src) and a negative regulatory phosphorylation site at its carboxyterminal at Tyr530 (Tyr527 in chicken Src). v-Src, the virallytransduced and mutated form of chicken Src, lacks several aminoacids at its carboxy-terminus, and therefore is only 526 amino acids in length. v-Src also possesses several additional point mutations (not shown here) which contribute to its transforming ability kinases in general (Johnson et al., 1996) . When this site becomes phosphorylated, it is displaced from the substrate binding pocket, allowing the kinase access to substrates (Xu et al., 1997 (Xu et al., , 1999 . Thus, when Tyr(416/419) is phosphorylated, it is a positive regulator of Src activity, and when dephosphorylated, it is a negative regulator of Src activity. Tyr(416/419) is a target for intermolecular autophosphorylation (Smart et al., 1981) and may also be a target of other tyrosine kinases, resulting in Src activation (Chiang and Sefton, 2000) . The importance of Tyr(416/419) autophosphorylation in normal c-Src regulation has been addressed by examining cells expressing c-Src protein possessing a Phe substitution at Tyr(416/419) (Kmiecik and Shalloway, 1987) . This Src mutant displays drastically reduced biological activity as compared to wild-type Src. Interestingly, mutation of Tyr(416/419) in the context of some transforming mutants of Src (i.e. vSrc) has more modest eects (Snyder and Bishop, 1984; Snyder et al., 1983) , suggesting that other alterations can perturb the normal regulatory processes imparted by the activation loop. Phosphorylation of Tyr(416/ 419) can also activate Src activity in the context of simultaneous phosphorylation at Tyr(527/530) (Boerner et al., 1996; Sun et al., 1998) , suggesting ®rst, that active Src phosphorylated at Tyr(416/419) cannot be fully inactivated by phosphorylation at Tyr(527/530) alone, but also requires dephosphorylation of Tyr(416/ 419). Secondly, this supports recent ®ndings that inactive Src family members may be the target of other kinases that can phosphorylate Tyr(416/419) and cause their activation (Chiang and Sefton, 2000) .
Other phosphorylation sites have been identi®ed within c-Src and are also thought to modulate the activity of the enzyme. During mitosis, phosphorylations within the unique domain of c-Src at Thr34, Thr46, and Ser72 (Shenoy et al., 1989) appear to destabilize the SH2/Tyr(527/530) interactions, thereby sensitizing c-Src to the action of a PTP capable of dephosphorylating Tyr(527/530) (Bagrodia et al., 1991 (Bagrodia et al., , 1994 Shenoy et al., 1992; Stover et al., 1994) , which leads to c-Src activation. c-Src is also a target of the activated PDGF receptor and becomes phosphorylated within its SH3 domain at Y138 (Broome and Hunter, 1997) and within its SH2 domain at Y213 (Stover et al., 1996) . Phosphorylation of these sites reduces the ability of these domains to bind ligands in vitro, suggesting that these phosphorylations can disrupt the Figure 2 Src is normally maintained in an inactive conformation (center) with the SH2 domain engaged with Tyr530, the SH3 domain engaged with the SH2-kinase linker, and Tyr419 dephosphorylated. Src activity is regulated by a variety of mechanisms, some of which are illustrated in detail here. Dephosphorylation of Tyr530 as a result of protein tyrosine phosphatase (PTP) action (right) disrupts the intramolecular interaction between the SH2 domain and Tyr530, Tyr419 can then become autophosphorylated, resulting in Src activation. Phosphorylation of Tyr530 by CSK allows this interaction to reform, resulting in Src inactivation. Binding of Src to tyrosine phosphorylated growth factor receptors via its SH2 domain (left) results in displacement of Tyr530, allowing Tyr419 phosphorylation and Src activation. Dissociation of Src from the growth factor receptor allows the intramolecular interactions to reform, resulting in Src inactivation. In addition to growth factor binding and Tyr530 dephosphorylation, a variety of SH2 and SH3 competitors may serve to alter Src structure, leading to Src activation. Some of these competitors may also serve to displace Tyr530 from SH2, allowing exposure to PTP, which would then activate Src by dephosphorylating Tyr530. Mutations within Src can also lead to disruption of the intramolecular interactions that stabilize Src in an inactive conformation, resulting in Src activation intramolecular interactions that stabilize the inactive conformation of Src. Although phosphorylation of Y138 has the potential to activate Src kinase activity and appears necessary for PDGF-induced DNA synthesis (Broome and Hunter, 1996) , this phosphorylation does not appear necessary for the observed elevations in c-Src activity following PDGF stimulation of cells (Broome and Hunter, 1997) . Y213, a site phosphorylated both in vitro by PDGF receptor and in vivo upon PDGF stimulation of Balb/c 3T3 cells (Stover et al., 1996) , also appears capable of activating Src and may be responsible for PDGF-mediated Src activation. Tyrosine sites within the unique domain of some Src-family members, in particular Hck, also appear to be the target of phosphorylation, with regulatory consequences. Hck can undergo autophosphorylation at Tyr29 within its unique domain in addition to phosphorylation on Tyr388 within its activation loop (Johnson et al., 2000) . Both of these phosphorylation events can lead to Hck activation. Src does not possess any tyrosine residues within its unique domain, and thus is unlikely to be regulated in this manner.
Regulation of Src activity through its interaction with binding proteins
The binding of Src to various proteins is thought to play an important role in Src regulation. This direct association can have at least two important regulatory consequences, including activation of the intrinsic tyrosine kinase activity of Src and relocalization of Src to sites of action.
Several structural features of Src and Src-family members facilitate interactions with proteins that regulate Src-family kinase activity. Biochemical and X-ray crystallographic analyses have revealed various internal interactions within the Src molecule, which maintain it in an inactive state. These include interactions between the SH2 domain and the carboxy-terminal tyrosine, Tyr(527/530), as well as interactions between the SH3 domain and the SH2-kinase linker (see Figure 2) . A variety of Src-binding proteins have been detected which can compete for binding to these components and disturb the intramolecular interactions, allowing for Src kinase activation. The platelet-derived growth factor receptor (PDGFR) (Kypta et al., 1990; Alonso et al., 1995) and focal adhesion kinase (FAK) (Cobb et al., 1994; Schaller et al., 1994; Eide et al., 1995) are examples of proteins that bind to the Src SH2 domain and activate Src. Nef and Sin (Alexandropoulos and Baltimore, 1996) are examples of proteins that can bind to SH3 domains and activate the Src-family members Hck and Src, respectively. Recently, p130
Cas , a protein that is thought to function as a docking protein because of its large number of binding motifs, has been demonstrated to bind to Src SH2 and SH3 domains, resulting in Src activation (Burnham et al., 2000) . No proteins have currently been identi®ed that can interrupt the intramolecular interactions and activate Src by binding to either the carboxy-terminal tyrosine or to the SH2-kinase linker. Such proteins, if they do exist, would represent two new classes of Src regulatory molecules.
The interaction of Src with binding proteins can also serve to either bring Src into direct contact with potential substrates and/or relocalize Src within the cell to bring it within close proximity to potential substrates. An example of regulation by localization is FAK autophosphorylation, which creates a binding site for the Src SH2 domain Eide et al., 1995) . Src can then associate with FAK in focal adhesions where it phosphorylates FAK, leading to further activation of FAK tyrosine kinase activity (Calalb et al., 1995) and downstream activation of the Ras, MEK, ERK pathway (Schlaepfer et al., 1998) . Src localization to focal adhesions also results in the phosphorylation of the cytoskeletal protein paxillin (Richardson et al., 1997) .
Factors that regulate the phosphorylation status of Tyr(527/530)
The phosphorylation status of Tyr(527/530), and therefore Src activity, is dependent upon a balance between the rate at which phosphate is removed by PTPs and the rate at which it is replaced by kinases. Under most normal circumstances, the Tyr(527/530) site is phosphorylated and Src is inactive in cells, suggesting that the net Tyr(527/530) phosphorylation exceeds Tyr(527/530) dephosphorylation. Factors that alter the balance between phosphorylation/dephosphorylation can cause changes in Src activity. In the next section, we will discuss the kinases and phosphatases responsible for maintaining this balance, and in particular, discuss what is known about how these proteins are regulated.
Phosphatases that dephosphorylate Tyr(527/530) ± PTP-a Several PTPs have been characterized as being capable of dephosphorylating Tyr(527/530) and are implicated in the regulation of c-Src tyrosine kinase activity. One PTP that can dephosphorylate the carboxy-terminal regulatory tyrosine of c-Src is PTP-a (Zheng et al., 1992) . PTP-a is a receptor-like PTP that is ubiquitously expressed, and is particularly abundant in brain tissue (Krueger et al., 1990; Kaplan et al., 1990a) . It was initially noted that when PTP-a was overexpressed in Fisher rat embryo ®broblasts, the stably-transfected cells exhibited a transformed phenotype (Zheng et al., 1992) . This phenotype included a rounded and refractile cellular morphology, lack of contact-inhibition, growth in multilayers, the ability to form foci, growth in low serum concentrations, anchorageindependent growth in soft agar, and tumor formation in nude mice. Examination of the phosphorylation status of c-Src in these cells revealed a pronounced reduction in the Tyr(527/530) phosphorylation level which was accompanied by an increase in c-Src tyrosine kinase activity. PTP-a also appeared to be able to dephosphorylate Tyr(416/419) as evidenced by the lack of Tyr(416/419) phosphorylation in PTP-a overexpressing cells (Zheng et al., 1992) and by the ability of chicken PTP-a to dephosphorylate v-Src in vitro (Fang et al., 1994a) .
PTP-a has also been demonstrated to dephosphorylate Tyr(527/530) and activate c-Src in P19 EC cells, where it has also been shown to alter the dierentiation fate of these cells in favor of neuronal dierentiation (den Hertog et al., 1993) . PTP-a overexpression can also dephosphorylate and activate c-Src in the human epidermoid carcinoma cell line A431, where it can also enhance cell-substratum adhesion, without altering growth characteristics of the cells (Harder et al., 1998) . Although most studies have addressed the eects of PTP-a on c-Src, it appears that other Srcfamily kinases may also be targets for dephosphorylation and activation by this particular PTP. c-Yes (Harder et al., 1998) as well as c-Fyn (Bhandari et al., 1998) have also been found to be both dephosphorylated and activated by PTP-a. This implies that PTP-a's eects on cells might not be limited to its eects on c-Src alone.
Thus, overexpression of PTP-a in a variety of cell types appears to increase c-Src and Src-family member kinase activities. Conversely, what happens when PTPa activity is reduced in cells? Antisense constructs have been employed to address this question and the results appear to corroborate the idea that PTP-a is a positive regulator of c-Src activity (Arnott et al., 1999) . Expression of antisense PTP-a in 3T3-L1 adipocytes reduces PTP-a levels in these cells and simultaneously reduces c-Src kinase activity. In addition to the antisense strategy of reducing PTP-a levels in cells, PTP-a 7/7 mice have also been generated and characterized (Ponniah et al., 1999; Su et al., 1999) . Although the mice appeared phenotypically normal, ®broblasts derived from the mice and mouse brain tissue were found to have signi®cantly reduced levels of both c-Src and c-Fyn tyrosine kinase activities. This reduction in kinase activity was accompanied by an enhanced phosphorylation of Tyr(527/530) in c-Src. Cellular characteristics and pathways downstream of Src were also aected. These included a reduction in spreading on ®bronectin, decreased phosphorylation of FAK and p130Cas, and a reduction in activation of MAP kinases .
Although there is evidence supporting a role for PTP-a in helping to maintain the overall phosphorylation status and activity of Src, it is still currently unknown whether PTP-a is regulated during any normal cellular signaling process such that it causes direct changes in c-Src activity. Investigations into PTP-a regulation are currently proceeding, and some data is now forthcoming that addresses this important question. PTP-a has been identi®ed as a target of phosphorylation by protein kinase C on two residues near its transmembrane domain (Tracy et al., 1995) and these phosphorylations result in stimulation of the protein's phosphatase activity (den Hertog et al., 1995) . Tyr789 in the carboxy-terminus of PTP-a is also a target for phosphorylation, perhaps by c-Src itself (den Hertog et al., 1994; Su et al., 1994) . This phosphorylation site appears to be a binding site for Grb2 (den Hertog et al., 1994; Su et al., 1994) ; as well it mediates the association of PTP-a with focal adhesion plaques (Lammers et al., 2000) , a known site of c-Src localization. Interestingly, experiments utilizing a Tyr789Phe mutant of PTP-a (Zheng et al., 2000) identi®ed this residue as being essential for PTP-a's ability to bind to, dephosphorylate, and activate c-Src. It also appeared necessary for the transforming ability of PTP-a. Experimental evidence suggests that Tyr789 might displace the SH2 domain of c-Src, thereby exposing the phosphorylated Src carboxy-terminal tyrosine to the action of the phosphatase (Zheng et al., 2000) .
Another mechanism by which PTP-a is proposed to be regulated is through dimerization (Bilwes et al., 1996; Majeti et al., 1998; Jiang et al., 1999 Jiang et al., , 2000 . Evidence derived from X-ray crystallography (Bilwes et al., 1996) and through the generation of stable disulphide-linked homodimers of PTP-a (Jiang et al., 1999) suggests that dimerization inhibits PTP-a activity. PTP-a dimers have recently been detected on the cell surface (Jiang et al., 2000) , suggesting that the process of dimerization may be important in cellular regulation of PTP-a phosphatase activity. The process of dimerization appears to require only the extracellular and transmembrane domains and the dimer is stabilized by multiple weak dimerization interfaces by a mechanism referred to as the`zipper model' (Jiang et al., 2000) . There is currently no physiological mechanism through which the formation/breakage of these dimers can occur. It is interesting to speculate that, like growth factor receptors, PTP-a may have a ligand that facilitates the stabilization of either monomeric or dimeric forms of PTP-a, which ultimately aects the protein's phosphatase activity. This postulated ligand might also be expected to play a role in the control of Src activity.
Protein tyrosine phosphatase l
Screening a chicken brain cDNA library with a probe corresponding to the intracellular domain of CD45 (a transmembrane PTP capable of dephosphorylating the Src-family member Lck) resulted in the identi®cation of a related transmembrane PTP that was named PTPl . PTPl transcripts are found abundantly expressed in spleen, intestine, and ®bro-blasts transformed by oncogenic ras or erbA/B. PTPl appears to be capable of dephosphorylating both Tyr(416/419) and Tyr(527/530) as evidenced by its ability to dephosphorylate both v-Src and c-Src. In studies comparing the activities of PTPl with chicken PTP-a and human leukocyte common antigen-related molecule (LAR) (Fang et al., 1994a) , all three PTPs were capable of dephosphorylating v-Src. However, only PTPl was capable of dephosphorylating and activating c-Src in both in vitro and in vivo experiments, thus inferring some degree of speci®city. The reason for the inability of PTP-a to dephosphorylate and activate c-Src in this particular model system is unknown.
Recently, PTPl has been implicated in the modulation of c-Src kinase activity in osteoclast precursor cells (Chappel et al., 1997) . The authors found that when osteoclast precursor cells were treated with 1,25-dihydroxyvitamin D 3 to induce dierentiation, there was a dramatic increase in cSrc speci®c activity in the absence of changes in c-Src protein levels. This change in activity was accompanied by a reduction in the phosphotyrosine content of c-Src, presumably on Tyr(527/530). Interestingly, both PTPl mRNA and protein levels were both upregulated, suggesting the possibility that PTPl might be responsible for the changes observed in cSrc kinase activity.
SHP-1
SHP-1, also known as PTP1C, is a cytosolic, dual SH2 domain-containing PTP that is expressed primarily in epithelial and hematopoietic cells. It has been found associated with c-Src in human platelets upon thrombin stimulation (Falet et al., 1996) . In addition, v-Src is capable of phosphorylating SHP-1 in SR-3Y1 cells, a v-Src transformed rat ®broblast cell line (Matozaki et al., 1994) .
Recently, evidence has been presented that also implicates SHP-1 in the dephosphorylation and activation of c-Src (Somani et al., 1997) . Interestingly, the authors found that although SHP-1 was capable of dephosphorylating both Tyr(416/419) and Tyr(527/ 530), it appeared to exert a more pronounced eect on Tyr(527/530), suggesting that SHP-1 may be more speci®c for Tyr(527/530). The authors also examined the status of c-Src in thymocytes derived from motheaten and viable motheaten mice (motheaten mice express reduced SHP-1 phosphatase activity due to loss-of-function mutations within the SHP-1 gene). Although the c-Src protein levels were similar in both types of motheaten mice and normal mice, there was a markedly lower level of c-Src tyrosine kinase activity in the motheaten and viable motheaten mice, accompanied by increased levels of phosphorylation on Tyr(527/530). In addition, dominant-negative SHP-1 expressed in HEY ovarian epithelial cancer cells resulted in reduced dephosphorylation of SHP-1 substrates and reduced c-Src kinase activity (Somani et al., 1997) .
SHP-2
Another cytoplasmic SH2 domain-containing PTP that has been implicated in regulating c-Src activity is SHP-2. SHP-2 was initially demonstrated to become phosphorylated in v-Src transformed cells (Feng et al., 1993) . Subsequently, Peng and Cartwright demonstrated that SHP-2 could bind to c-Src, that an activated mutant form of Src could phosphorylate SHP-2, and that Tyr(527/530) of c-Src could be dephosphorylated by SHP-2 (Peng and Cartwright, 1995) . SHP-2 appeared to be relatively speci®c for Tyr(527/530) in vitro, where 50% dephosphorylation of Tyr(527/530) by SHP-2 was accompanied by no signi®cant dephosphorylation of Tyr(416/419) (Peng and Cartwright, 1995) . SHP-2 was later demonstrated to be capable of activating c-Src activity in vivo by examining the eects of in vivo SHP-2 overexpression (Walter et al., 1999) . Interestingly, elevations in c-Src activity were not accompanied by signi®cant changes in the phosphorylation status of Tyr(527/530) or Tyr(416/ 419). In addition, a phosphatase-inactive mutant of SHP-2 was also capable of c-Src activation. This result coupled with the ®nding that SHP-2 associates with cSrc by binding to its SH3 domain suggested that perhaps most, or all, of the c-Src-activating activity of SHP-2 in vivo might be due to a mechanism not involving c-Src dephosphorylation. Instead, it may involve binding to the c-Src SH3 domain, with the resulting allosteric activation of Src. The use of antisense oligonucleotides to reduce SHP-2 levels in 3T3 cells transfected with c-Src resulted in decreased cSrc speci®c activity (Walter et al., 1999) , further supporting a possible role of SHP-2 in the control of c-Src activity, possibly through a non-enzymatic mechanism.
PTP1B and other PTPs that might target c-Src
Rather than screen identi®ed PTPs for activity against cSrc, some laboratories, including our own, have adopted a dierent approach, and have ®rst identi®ed cell types where there are measurable elevations in c-Src speci®c activity. This approach is of particular relevance because several dierent PTPs are known to target Src for dephosphorylation and activation, and the expression pattern of these PTPs varies according to cell type. Two cell types that have been identi®ed by our laboratory as possessing elevated Src activity are human melanocytes (O'Connor et al., 1992 (O'Connor et al., , 1995 and several human breast cancer cell lines (Egan et al., 1999) . In both situations, we have detected elevated c-Src speci®c activity and hypophosphorylation of Tyr(527/530). Interestingly, these cells also have elevated levels of PTP activity capable of dephosphorylating a synthetic peptide modeled against the carboxy-terminus of Src-family members. We have hypothesized that this PTP activity may have an important role in controlling c-Src activity and the cell phenotype. In the human breast cancer cell lines in particular, high levels of PTP activity directed against Tyr(527/530) may contribute to c-Src activation, and may be important in maintaining the transformed phenotype. This activation of Src could occur independently, or in conjunction with activated receptor tyrosine kinases, and might promote Src activation in either a direct, additive, or synergistic manner. We have puri®ed the major PTP activity from breast cancer cell lines that is capable of dephosphorylating the carboxy-terminal synthetic peptide and c-Src, and identi®ed it as PTP1B (Bjorge et al., submitted) . PTP1B protein levels were found to be elevated in several breast cancer cell lines and PTP1B was found to be capable of both in vitro and in vivo activation of c-Src kinase activity as a result of its ability to dephosphorylate Tyr(527/530). These results suggest that PTP1B may have an important role to play in the regulation of Src activity and that it may also contribute to Src activation in some forms of human cancer. The ability of PTP1B to modulate Src activity has also been demonstrated in mouse L cell ®broblasts (Arregui et al., 1998) . A dominant negative form of PTP1B was shown to reduce Src activity and this was attributed to increased phosphorylation of Tyr(527/530).
PTPs have also been implicated in Src activation that occurs as a result of activation of G-protein coupled receptors. Src speci®c activity has been found to be transiently elevated in platelets stimulated with thrombin, and this was accompanied by a reduction in the phosphorylation of Tyr(527/530) (Clark and Brugge, 1993) . Interestingly, SHP-1, a PTP that has been implicated in the dephosphorylation of Tyr(527/530) (see previous section on PTPs), has also been shown to become activated upon thrombin stimulation of platelets (Li et al., 1995) . Bombesin or vasopressin stimulation of Swiss 3T3 cells have been shown to result in Src activation, and this activation was completely blocked by treatment of the cells with vanadate, a PTP inhibitor (Rodriguez-Fernandez and Rozengurt, 1996) . Recently, bradykinin has also been demonstrated to activate Src, and this was accompa-nied by the activation of PTP activity that could dephosphorylate the synthetic phosphopeptide substrate Raytide (Graness et al., 2000) . Although further experimentation will be required to prove that the elevated PTP activity is responsible for the observed increases in Src activity, this data certainly suggests that the modulation of PTP activity may have an important role in controlling Src kinase activity in the G-protein coupled receptor system.
Kinases that phosphorylate Tyr(527/530) Two tyrosine kinases, CSK (c-Src kinase) and CHK (CSK homologous kinase), have been identi®ed that are capable of phosphorylating Src on Tyr(527/530) and inactivating its kinase activity. CSK was puri®ed on the basis of its ability to phosphorylate the carboxyterminal tyrosine of c-Src (Okada and Nakagawa, 1989) . CSK is structurally related to Src-family kinases, but lacks a myristoylation signal and phosphorylation sites corresponding to Tyr(416/419) and Tyr(527/530) . CSK is expressed ubiquitiously, but is most abundant in thymus, spleen, and neonatal brain tissue . This enzyme is capable of phosphorylating Tyr(527/530) and inactivating c-Src both in vitro and in vivo . Mice lacking the enzyme (CSK 7/7) have neural tube defects and die between days 9 and 10 of gestation (Nada et al., 1993; Imamoto and Soriano, 1993) . Cells derived from these embryos have highly elevated c-Src, c-Fyn, and c-Lyn kinase activities, accompanied by hypophosphorylation of Tyr(527/530) and hyperphosphorylation of Tyr(416/419) (Nada et al., 1993; Imamoto and Soriano, 1993) .
Although Src-family kinases share many characteristics with CSK (i.e. SH3, SH2, and kinase domain), the lack of an autophosphorylation site and a negative regulatory carboxy-terminal tyrosine in CSK suggests that this protein has a very dierent mechanism of regulation. CSK is phosphorylated on Tyr-184 in vivo, but the identity of the kinase responsible for this phosphorylation and its potential role in CSK regulation are presently unknown (Joukov et al., 1997) . Ser/Thr phosphorylation of CSK has also been proposed to be an important mechanism in regulating CSK activity. Phosphorylation by cAMP-dependent kinase has been found to reduce CSK activity in vitro (Sun et al., 1997) . CSK appears to translocate to subcellular sites where its activity is probably required for normal regulation of Src-family kinases (Howell and Cooper, 1994) . A number of CSK binding proteins have been identi®ed that may play an important role in membrane localization of CSK, and include GTPase-activating protein (GAP)-associated p62 (p62dok) (Neet and Hunter, 1995; Yamanashi and Baltimore, 1997; Carpino et al., 1997) and the Src-family member Lck (Bougeret et al., 1996) .
Recently, new insights into how CSK might be regulated have been obtained by two groups of investigators who have discovered another protein capable of binding CSK. This protein, named CSK binding protein (Cbp) or phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG) (Kawabuchi et al., 2000; Brdicka et al., 2000) , is a ubiquitously expressed transmembrane phosphoprotein that is localized in the GM1 ganglioside-enriched membrane domains. It was initially identi®ed and ®nally puri®ed and cloned based upon its ability to bind to CSK (Kawabuchi et al., 2000) and its localization to glycosphingolipid-enriched membrane microdomains (GEMs) (Brdicka et al., 2000) . Cbp/ PAG binds to and recruits CSK to the plasma membrane by virtue of a tyrosine phosphorylation site on Cbp/PAG and the SH2 domain in CSK. Binding of Cbp/PAG to CSK also appears to activate CSK (Takeuchi et al., 2000) . The tyrosine kinase responsible for the phosphorylation of Cbp/PAG is currently unknown. However, it has been proposed that a Srcfamily member itself may well be the kinase responsible for this phosphorylation event. It is thought that this may be a form of autoregulation in which activated cSrc phosphorylates Cbp/PAG, which in turn, recruits CSK to the membrane, where it can then phosphorylate and negatively regulate Src activity. Kawabuchi et al. (Kawabuchi et al., 2000) have demonstrated the ability of Cbp/PAG to regulate c-Src activity by overexpressing Cbp/PAG in COS7 cells. Their results show that upon Cbp/PAG overexpression, CSK becomes colocalized with Cbp/PAG, and c-Src kinase activity is inhibited. Furthermore, Brdicka et al. (Brdicka et al., 2000) have demonstrated that in resting T cells, Cbp/PAG is constitutively phosphorylated on tyrosine residues. Upon T cell activation, there is a rapid dephosphorylation of Cbp/PAG, dissociation of CSK from Cpb/PAG, and activation of Src family members. It will be interesting to identify the PTP responsible for dephosphorylation of Cbp/PAG. It remains to be determined whether PTPs previously identi®ed as being able to dephosphorylate Tyr(527/ 530) and activate c-Src, such as PTP-a, are also capable of dephosphorylating Cbp/PAG. If so, this would suggest the existence of an alternative regulatory mechanism for reducing Tyr(527/530) phosphorylation, one that possibly utilizes reductions in CSK activity, rather than increases in Tyr(527/530) phosphatase activity.
Other proteins that bind to CSK and may be important for Src regulation include two structurally related non-receptor PTPs, PEP (proline-enriched protein tyrosine phosphatase) (Cloutier and Veillette, 1996) and PTP-PEST (Davidson et al., 1997a) , a nonreceptor PTP possessing features of PEST motifs which are found in proteins with very short intracellular halflives (Yang et al., 1993) . Although PEP is expressed exclusively in hematopoietic cells, PTP-PEST is expressed ubiquitously. PEP, the better characterized of the two proteins, has been shown to dephosphorylate the autophosphorylation site of the Src-family member FynT (an isoform of Fyn that is expressed primarily in T-lymphocytes) when overexpressed, thereby inactivating FynT kinase activity (Coultier and Veillette, 1999) . Overexpression of PEP also resulted in a general reduction in the phosphorylation status of a number of proteins and the inhibition of T-cell receptor signaling. PEP's ability to dephosphorylate the positive regulatory site of Src-family members coupled with the ability of CSK to phosphorylate the negative regulatory site makes this PEP/CSK complex a potent negative regulator of Src-family function. Although PTP-PEST has not yet been characterized with regard to its ability to inactivate Src-family members, it is interesting to speculate that due to its formation of a complex with CSK and its ubiquitous expression, that it too may be a prime candidate for regulating the kinase activity of Src-family members such as Src.
Recently, data suggesting that alterations in CSK activity might play a role in human hepatocellular carcinoma have been reported (Masaki et al., 1999) . CSK activity has been found to be reduced in tumorous liver tissue when compared to normal control tissue. The investigators noted a slight upward shift in the molecular weight of CSK upon immunoblot analysis, and suggested the possibility that an alternate isoform of CSK is present in the tumorous tissue. These results suggest a potential role for CSK in human cancers, and might explain reports of elevations of Src kinase activity in this type of cancer (Masaki et al., 1998) .
A protein related to CSK has also been cloned by a number of groups (Klages et al., 1994) and is also able to regulate Src activity by phosphorylation of Tyr(527/ 530) (Chow et al., 1994; Sakano et al., 1994; Bennett et al., 1994; McVicar et al., 1994) . Initially, some confusion arose because it wasn't readily apparent whether all of these cloned proteins were derived from the same gene. It is now recognized that these proteins are all probably derived from the same gene and dierences between the proteins are probably due to alternative splicing (Grgurevich et al., 1997) . The name CHK (CSK homologous kinase) has been adopted by most investigators. CHK is related to CSK, but tends to be expressed primarily in brain and hematopoietic cells. In contrast to the rather dramatic phenotype exhibited by CSK 7/7 mice, CHK 7/7 mice exhibit no detectable phenotype, even in cells of hematopoietic lineage (Hamaguchi et al., 1996; Samokhvalov et al., 1997) , suggesting that CHK probably has dierent cellular functions than CSK. The similarities and dierences in function between CSK and CHK have been highlighted in a paper by Davidson et al. (Davidson et al., 1997b) . Both CSK and CHK were found to suppress Src-family kinase activity in CSK 7/7 ®broblasts, but only CSK could suppress antigen-induced signals in the T-cell line BI-141. This dierence was attributed to the inability of membranetargeting sequences added to CHK to eciently target CHK to cellular membranes, whereas this approach could eciently target CSK to cellular membranes. It was postulated that other unidenti®ed targeting signals within CHK might be more dominant than the membrane-targeting sequence added to CHK.
Src localization
Studies on the subcellular localization of Src have provided numerous clues as to its function. Although the normal function of Src still remains largely unclear at present, it has been found to associate with cellular membranes, in particular the plasma membrane, the perinuclear membrane and endosomal membranes (Willingham et al., 1979; Courtneidge et al., 1980; Resh and Erikson, 1985; David Pfeuty and NouvianDooghe, 1990; Kaplan et al., 1992) . At the plasma membrane Src is thought to be involved in signal transduction events regulating cell growth and proliferation via activated growth factor receptors. Initial studies on the localization of v-Src in Schmidt-Ruppin avian sarcoma virus (ASV)-transformed NRK cells demonstrated the protein to be concentrated on the inner surface of the plasma membrane, particularly under rues (Willingham et al., 1979) . Similarly, the cellular homologue of the viral transforming protein, cSrc, has also been demonstrated to associate with the plasma membrane (Courtneidge et al., 1980) . Subsequent work has shown Src localization in focal adhesion plaques and at adherens junctions between cells (Henderson and Rohrschneider, 1987; Owens et al., 2000) . This localization of Src to the cell periphery, in particular focal adhesions and cell-cell contacts has been demonstrated to be dependent on the intact actin cytoskeleton (Fincham et al., 1996; Owens et al., 2000) .
In addition to being associated with plasma membranes in ®broblasts (typically at sites of focal adhesion (Kaplan et al., 1994) ), both viral and cellular Src proteins have also been detected in the cytoplasm and in the perinuclear Golgi region of the cell (Willingham et al., 1979; Resh and Erikson, 1985) . In particular, 30 ± 40% of the total Src population is localized to the perinuclear region of the cell (Tanaka and Kurth, 1984; Resh and Erikson, 1985) . In Schmidt-Ruppin ASV-transformed NRK cells, *60% of v-Src has been found to be associated with the cytosol, in comparison to *40% with the plasma membrane (Willingham et al., 1979) . The dierent subcellular localizations of Src within cells are indicated in Table 1 .
Membrane association of Src is in part due to a postranslational modi®cation at its amino terminus ± Willingham et al., 1979; Courtneidge et al., 1980; Focal adhesions; actin factor RTKs** and GPCRs; cell Resh and Erikson, 1985; Henderson and Rohrschneider, 1987; cytoskeleton; microtubule adhesion and spreading; cell Kaplan et al., 1992; Twamley-Stein et al., 1993; Kaplan et al., 1994 ; bundles at points of cell-cell migration; cell-cell contact Okamura and Resh, 1994; Fincham et al., 1996; Li et al., 1996; contact; adherens junctions; Luttrell et al., 1996; Schaller et al., 1999; Fincham et al., 2000; caveolae Owens et al., 2000 Cytoplasmic and perinuclear Protein trafficking; endosomal Willingham et al., 1979; Tanaka and Kurth, 1984 the covalent attachment of a 14-carbon fatty acid moiety, myristate (Buss and Sefton, 1985; Schultz et al., 1985; Kaplan et al., 1988) . However, myristoylation is not sucient for membrane anchorage (Kaplan et al., 1990b) . Instead, other residues of Src in conjunction with myristoylation are required for mediating membrane association (Kaplan et al., 1990b) . In particular, six basic residues at the amino terminus are essential for high anity binding to lipid bilayers (Sigal et al., 1994) . Moreover, three regions at the Nterminus have been identi®ed that regulate the subcellular localization of Src. The region containing amino acids 1 ± 14 of Src is sucient to mediate both the myristoylation and the attachment of fusion protein constructs to cytoplasmic granules (Kaplan et al., 1990b) . In contrast, amino acids 38 ± 111 of Src cause proteins to associate with plasma membranes and perinuclear membranes, whereas amino acids 204 ± 259 mediate association primarily with perinuclear membranes (Kaplan et al., 1990b) . Although myristoylation is not sucient for membrane anchorage, the myristate group is necessary for the perinuclear retention of kinase inactive Src molecules (Fincham and Frame, 1998) . Interestingly, myristoylation of Src may also prevent its unregulated transport into the nucleus, thus suggesting that a subpopulation of Src may exist that exerts speci®c functions at speci®c times of the cell cycle within the nucleus (David-Pfeuty et al., 1993) . In cells overexpressing a nonmyristoylated mutant form of c-Src, starting in G2 phase and during mitosis, myristoylation-defective c-Src proteins translocate to the nucleus and associate with a number of components that participate in mitotic events, such as spindle poles and ®bers, and interchromosomal material (David-Pfeuty et al., 1993) . Furthermore, c-Src has been found to localize within both the nucleus and nucleolus (David-Pfeuty and Nouvian-Dooghe, 1995). Thus, it has been proposed that Src may regulate progression through the cell cycle and entry into mitosis by interacting with cell division regulatory components at the nuclear level (David-Pfeuty et al., 1993; David-Pfeuty and Nouvian-Dooghe, 1995) . Interestingly, it has been shown that Src deletion mutants lacking the amino-terminal one-third of v-Src, including the membrane binding domain are still capable of inducing cell proliferation, although they do not cause morphological transformation (Calothy et al., 1987) . These results demonstrate that the target(s) involved in mitogenic activity is accessible to unmyristoylated Src and that the mitogenic response may be dependent on a Src substrate(s) that is not localized at the plasma membrane (Calothy et al., 1987) . Studies have shown that v-Src stably interacts with a detergent-insoluble cytoskeleton matrix, whereas c-Src does not (Burr et al., 1980; Loeb et al., 1987) . This dierence in ability to interact with the cytoskeletal matrix is modulated by the Src catalytic domain, which works in conjunction with its SH2 domain to determine the protein's ability to associate with the cytoskeleton (Okamura and Resh, 1994) . However, the assembly of v-Src into actin-associated focal adhesions does not require its catalytic activity or its myristoylation site (Fincham and Frame, 1998) . Instead, the SH3 domain mediates the switch from a microtubuledependent perinuclear localization to actin-associated focal adhesions (Fincham et al., 2000) . Furthermore, the translocation of v-Src to peripheral focal adhesions requires the v-Src SH3 dependent association and activation of phosphatidylinositol (PI) 3-kinase (Fincham et al., 2000) . In contrast, c-Src requires its myristoylation site as well as the SH3 domain for localization to focal adhesions (Kaplan et al., 1994) . Interestingly, activation of c-Src also appears to be important in its subcellular localization (Kaplan et al., 1994 (Kaplan et al., , 1995 . Mutation of the regulatory Tyr(527/530) to a phenylalanine has been shown to dramatically redistribute c-Src from endosomal membranes to focal adhesions, suggesting that the phosphorylation status of this tyrosine residue aects Src localization (Kaplan et al., 1994) . Moreover, the SH2 domain of c-Src, through its association with FAK, has also been suggested to be an important mechanism in regulating the protein's subcellular localization (Cobb et al., 1994; Schaller et al., 1994 Schaller et al., , 1999 .
Although much evidence has been acquired regarding the role of Src at the plasma membrane and its interaction with growth factor receptors and integrinnucleated focal adhesion complexes (see reviews by Abram and Courtneidge, 2000; Biscardi et al., 1999; Thomas and Brugge, 1997) , the functional signi®cance of Src at other subcellular locations such as cytoplasmic granules and perinuclear membranes has not been well characterized. The punctate staining pattern Src exhibits in ®broblasts is thought to represent the protein's association with membrane vesicles. Furthermore, analysis of c-Src in NIH c-src overexpresser cells indicates a possible association of Src with endosomal membranes (David-Pfeuty and Nouvian-Dooghe, 1990). Analysis of indirect immuno¯uorescence by three-dimensional optical sectioning microscopy revealed Src to be primarily associated with membranes at the microtubule organizing center (MTOC) that represent a late stage in the endocytic pathway (Kaplan et al., 1992) . This data contrasts with and extends previous reports demonstrating Src localization at the plasma membrane. One explanation for this discrepancy has been attributed to the fact that biochemical fractionation techniques used in some prior studies did not dierentiate between plasma membranes and endosomal membranes, which have similar densities and are thus likely to cofractionate (Kaplan et al., 1992) . Moreover, c-Src has also been demonstrated to co-localize with a number of microtubule-related structures, including microtubule bundles at points of cell-cell contact, the MTOC and a region associated with the spindle poles during mitosis (Kaplan et al., 1992) . Interestingly, this association was dependent on intact microtubules, suggesting that c-Src associates with the microtubule cytoskeleton via endocytic vesicles (Kaplan et al., 1992) . This evidence highlights a potential role for Src in regulating the transport or function of specialized secretory vesicles (Kaplan et al., 1992) . The presence of Src in secretory organelles of chroman cells and platelets (Parsons and Creutz, 1986; Rendu et al., 1989) , its association with endosomally-derived synaptic vesicles in dierentiated PC-12 cells (Linstedt et al., 1992) , and the development of osteopetrosis in mice that are null for Src (Soriano et al., 1991) further point to a possible role for Src in protein tracking events. Osteoclasts that dissolve bone are highly specialized secretory cells that secrete lysosomal enzymes, and the absence of Src is thought to disrupt the regulatory processes necessary for tracking lysosomal proteins (Kaplan et al., 1992) . Inhibition of Src kinase activity by the Src tyrosine kinase inhibitor PP1 supports this notion, as it has been demonstrated to suppress collagenolytic protease secretion in osteoclasts, and ultimately bone resorption (Furuyama and Fujisawa, 2000) .
The signi®cance of Src localization to endosomal and perinuclear membranes remains to be determined. However, it is interesting to note that in breast cancer tissue, Src exhibits a predominantly perinuclear pattern in malignant cells, in contrast to a more evenly distributed cytoplasmic pattern characteristic of normal breast epithelial cells (Verbeek et al., 1996) . Also, at the onset of transformation, polyomavirus middle-T recruits Src to a perinuclear compartment coincident with condensation of tubular endosomes (Zhu et al., 1998) . It has been suggested that this pronounced staining around the nucleus could re¯ect the localization of Src to endosomal membranes, where it might function to enhance the mitotic activity of cells by somehow mediating mitotic eects of Cdc2 or other eectors (Chackalaparampil and Shalloway, 1988; Kaplan et al., 1992; Verbeek et al., 1996) .
Nuclear and perinuclear targets of Src
The localization of Src to perinuclear membranes, endosomes, and possibly even the nucleus suggests that Src is involved in signal transduction events that do not always involve the plasma membrane. However, limited information exists with respect to Src function at these intracellular locations, and in particular, the speci®c substrates with which Src may interact. Thus, the identi®cation of Src targets at these subcellular domains is an essential starting point for the elucidation of the biological functions of Src kinase molecules localized to these regions.
The tyrosine kinase activity of Src is increased in mitotic cells arrested with the drug nocodazole (Chackalaparampil and Shalloway, 1988; Shenoy et al., 1989; Morgan et al., 1989; Bagrodia et al., 1991; Kaech et al., 1991; Shenoy et al., 1992; Taylor and Shalloway, 1993) . Although the function of this activation is not yet completely understood, there is growing evidence which suggests that Src may play a role in the regulation of the cell cycle Shalloway, 1993, 1996) . Studies have been performed which have identi®ed a phosphorylated 68 kDa protein that not only associates with, but is tyrosine phosphorylated by overexpressed wild-type or mutationally activated forms of c-Src during mitosis in mouse ®broblasts (Fumagalli et al., 1994; Taylor and Shalloway, 1994) . This protein has been designated Sam68 (Src-associated in mitosis). An identical protein, called p70, was identi®ed as a tyrosinephosphorylated protein that was capable of binding the Lck SH2 domain (Vogel and Fujita, 1995) . This protein was found to be constitutively phosphorylated in leukemic T-cells, and became tyrosine phosphorylated within minutes after stimulation of resting Tcells with phytohemagglutinin or interleukin-2, suggesting that its tyrosine phosphorylation was not limited to mitosis (Vogel and Fujita, 1995) . Initially, some confusion in nomenclature may have arisen as Sam68/p70 was initially cloned and described as the GAP-associated tyrosine phosphoprotein p62 that could associate with both mRNA and DNA (Wong et al., 1992; Lock et al., 1996) .
Sam68 is a nuclear protein that consists of at least six proline rich regions, an RNA binding region referred to as the hnRNP K homology (KH) domain (Gibson et al., 1993; Siomi et al., 1993) and a tyrosinerich C-terminal region (Wong et al., 1992; Fumagalli et al., 1994; Chen et al., 1997; Ishidate et al., 1997) . Sam68 binds to poly(U) homopolymeric ribonucleotides, in vitro (Taylor and Shalloway, 1994; , and its ability to bind ribonucleotides can be negatively regulated by tyrosine phosphorylation, as well as by interactions with the Src SH3 domain (Taylor et al., 1995; Wang et al., 1995) . Both the SH3 and SH2 domains of Src are required for stable interactions with Sam68 during mitosis (Fumagalli et al., 1994; Taylor and Shalloway, 1994; Taylor et al., 1995) .
It has been suggested that Src phosphorylation of Sam68 may be important in regulating events during mitosis (Pillay et al., 1996) . The drug radicicol (a potent inhibitor of Src kinase activity) has been demonstrated to reversibly inhibit Sam68 tyrosine phosphorylation by mitotic Src and the subsequent exit from mitosis of Src-transformed cells, whereas it has no eect on the ability of cells to enter mitosis, as determined by¯ow cytometric analyses (Pillay et al., 1996) . This suggests that Src is important in the regulation of cell cycle function via Sam68, particularly during the later stages of mitosis (Pillay et al., 1996) .
The identi®cation of a naturally occurring isoform of Sam68 with a deletion within the KH domain (Sam68DKH) further supports a role for Sam68 in regulating cell cycle progression (Barlat et al., 1997) and its potential function in mediating cell cycle signals generated by Src. Upon growth arrest of con¯uent cultures of normal cells, expression of Sam68DKH is increased, whereas no expression of this isoform is observed in cells incapable of entering quiescence at con¯uency, such as Src-transformed cells (Barlat et al., 1997) . Transfected Sam68DKH inhibits serum-induced DNA synthesis, whereas Sam68 overcomes this eect (Barlat et al., 1997) . As a result, it has been proposed that Sam68-isoforms, through their KH domain, are involved in regulating cell proliferation, more precisely at the G1/S transition (Barlat et al., 1997) . Src activity also appears to be required during this stage of the cell cycle and is necessary for committing cells to S phase (Wyke et al., 1993 (Wyke et al., , 1995 . Interestingly, constitutive tyrosine phosphorylation of Sam68 is thought to aect the cell cycle in T-cells (Fusaki et al., 1997) , and constitutive tyrosine phosphorylation of Sam68 has also been observed in leukemic T-cells (Vogel and Fujita, 1995) .
Although Sam68 was initially identi®ed as a tyrosine phosphorylated target of Src in cells overexpressing wild-type or mutationally activated forms of c-Src during mitosis (Fumagalli et al., 1994; Taylor and Shalloway, 1994) , it is interesting to note that in a subsequent study, the metabolic labeling of untransfected HeLa and NIH3T3 cells with [ 32 P]orthophosphate demonstrated that Sam68 was phosphorylated on threonine residues exclusively during mitosis, as well as on serine residues during both interphase and mitosis (Resnick et al., 1997) . No tyrosine phosphorylation signals on Sam68 were observed under these conditions (Resnick et al., 1997) . Cdc2 was identi®ed as the kinase responsible for the threonine phosphorylation of Sam68 during mitosis, with no eect on Sam68-RNA interactions (Resnick et al., 1997) .
It has been postulated that Src regulates gene expression at the post-transcriptional level via Sam68 and evidence indicates that Src can act on the general mechanism of splicing and/or mRNA transport. Using the murine tumor necrosis factor b (TNFb) gene as a reporter for pre-mRNA processing, co-transfection with an expression vector containing Src cDNA into NIH3T3 cells was shown to induce a modi®cation of RNA processing (Neel et al., 1995) . Comparison of several modes of Src activation demonstrated that Src could either slow down the splicing rate or allow export of partially spliced transcripts (Neel et al., 1995) . Interestingly, overexpression of an activated form of the Src family kinase Fyn in HEK293 cells has been observed to phosphorylate Sam68 and negatively regulate its association with the splicingassociated factor YT521-B (Hartmann et al., 1999) . However, a recent study has demonstrated that RNA transport and splicing of Lymphotoxin a transcripts are insensitive to the deletion of the Src SH3 domain, thus indirectly ruling out Sam68 as a potential regulator of these mRNA processing events via Src (Gondran and Dautry, 1999) . Mutation of the Src SH3 domain has been shown to disrupt its association with Sam68 (Taylor and Shalloway, 1994) . However, the Src SH3 mutant used in this study also contained an activating Src mutation (Gondran and Dautry, 1999) . This raises the possibility that Src may have still been able to phosphorylate Sam68 and interact with the RNA binding protein through its SH2 domain. Interestingly, mutating the SH2 domain of Src aected the RNA transport phenotype, and disruption of the tyrosine kinase domain aected both splicing and transport phenotypes (Gondran and Dautry, 1999) .
Currently, Sam68 and Src are thought to interact only upon nuclear envelope breakdown during mitosis. However, there is evidence that suggests a constitutive association between Src and Sam68 throughout the cell cycle (Pillay et al., 1996) . Furthermore, the early involvement of Sam68 in T-cell signaling suggests the existence of a non-nuclear population of Sam68, whose possible function may be to serve as an adaptor molecule (Vogel and Fujita, 1995; Fusaki et al., 1997; Lang et al., 1999) . Studies in T-cells indicate that Sam68 may function as an adaptor linking the TCRcoupled Src family kinases Fyn and Lck to downstream eectors (Vogel and Fujita, 1995; Fusaki et al., 1997; Lang et al., 1999) . Numerous other partnerships with dierent SH2 and SH3 domain-containing signaling molecules have also been documented including: PLCg-1, Grb2, Nck, Jak3, SHP-1, Cbl, Grap (Grb2-like protein), the p21 ras GTPase activating protein, the p85 subunit of PI3-kinase, p47 phox and Tec kinase family Finan et al., 1996; Bunnell et al., 1996; Fusaki et al., 1997; Guinamard et al., 1997; Jabado et al., 1997 Jabado et al., , 1998 Lawe et al., 1997; Trub et al., 1997; Guitard et al., 1998) .
Recently, it has been demonstrated that murine Src-related intestinal kinase (Sik) (Siyanova et al., 1994) and its orthologue human breast tumor kinase (BRK) (Mitchell et al., 1994; Llor et al., 1999) , two intracellular tyrosine kinases that are distantly related to the Src kinase family, can associate with Sam68 (Derry et al., 2000) . Both Sik and BRK colocalize with Sam68 in the nucleus (Derry et al., 2000) . More speci®cally, BRK colocalizes with Sam68 in nuclear bodies called Sam68-SLM nuclear bodies (SNBs) in both breast and colon tumor cell lines (Derry et al., 2000) . Furthermore, Sik can tyrosine phosphorylate Sam68 in vivo and negatively regulate its RNA binding ability (Derry et al., 2000) . Sik expression in cells can also abolish the ability of Sam68 to act as a cellular homologue of Rev, a protein which plays an essential role in the nuclear export of unspliced or partially spliced viral transcripts (Derry et al., 2000) . Although Src has been demonstrated to interact with Sam68 during mitosis, Sik/BRK is the ®rst tyrosine kinase that has been shown to phosphorylate Sam68 within the intact nucleus and regulate its RNA binding ability. Interestingly, Sik has a very short unique amino terminus and, unlike Src, is not myristoylated (Vasioukhin et al., 1995) , a modi®cation that is thought to prevent the transport of Src into the nucleus (David-Pfeuty et al., 1993) . In this respect, it would be interesting to speculate whether a subpopulation of unmyristoylated Src protein exists within cells that can translocate to the nucleus to exert speci®c functions at speci®c times of the cell cycle via Sam68. Lastly, it is also important to note that plasma membrane localization of Fyn has also been demonstrated to be essential for the constitutive tyrosine phosphorylation of nuclear Sam68 and that phosphorylation of Sam68 can occur outside the nucleus, suggesting that Sam68 molecules can accumulate within the nucleus after they become phosphorylated (Lang et al., 1999) .
The identi®cation of nuclear targets of Src strengthens its role in mediating cellular events that do not necessarily involve its presence at the plasma membrane. This further supports the notion that dierential localization patterns of Src serve a speci®c cellular function, which may be clari®ed by the identi®cation of its substrates at these particular subcellular locations. Attempts to identify additional targets of Src are thus useful for the elucidation of the normal function of Src within the cell. ASAP1, an Arf (ADP-ribosylation factor) GTPase-activating protein was identi®ed in a screen for proteins that interact with the SH3 domain of Src (Brown et al., 1998) . The protein is mostly found in the cytoplasm in a perinuclear, reticulate network in cells transfected with an ASAP1 expression vector (Brown et al., 1998) . It coimmunoprecipitates with Src and becomes tyrosine phosphorylated in cells expressing an activated mutant form of Src (Brown et al., 1998) . The association of ASAP1 with Src, Arfs and PIP 2 is thought to be important in coordinating membrane tracking with actin cytoskeletal remodeling (Brown et al., 1998; Randazzo et al., 2000) . Interestingly, Src associates with and/or phosphorylates various proteins implicated in vesicle transport, including synapsin I, dynamin, synaptophysin, synaptogyrin, and cellugyrin (Barnekow et al., 1990; Onofri et al., 1997; Foster-Barber and Bishop, 1998; Janz and Sudhof, 1998) . Furthermore, a Golgi protein that may be involved in vesicle docking/tethering, desig-nated golgin-67, has also been identi®ed as a potential Src target (Jakymiw et al., 2000) . Puri®ed baculovirus c-Src has been shown to associate with and tyrosine phosphorylate golgin-67 in vitro (Raharjo et al., unpublished data) but further studies will be required to provide information concerning the functional consequences of Src interactions with golgin-67. Cumulatively, this evidence suggest that Src might have a role in regulating membrane tracking events, with possible links to the Golgi apparatus (DavidPfeuty and Nouvian-Dooghe, 1990; Abu-Amer et al., 1997) . In osteoclasts, Src is localized to speci®c intracellular fractions that contain Golgi-derived membranes . It is thought that Src not only governs the formation of the rued membrane in osteoclasts, but is itself packaged within sub-Golgi vesicles that are transported to the boneapposed plasma membrane (Abu-Amer et al., 1997). In Rat-1 ®broblasts over-expressing chicken c-Src, Src is localized to late endosomal membranes (Kaplan et al., 1992) . However, it is interesting to note that in this study no direct attempt was made to distinguish between endosomes and the trans-Golgi Network (TGN), thus raising the possibility that Src may regulate protein tracking events that may involve the TGN.
Involvement of c-Src human cancers
This topic is discussed in more detail in the review article by Yeatman and colleagues in this issue of Oncogene, and in other reviews (Biscardi et al., 1999) , so our discussion of it will be limited to a very short summary of a few relevant concepts and experimental ®ndings.
For many years it was widely believed that Src would be found to be involved in the development or progression of at least some types of human cancers, especially in light of the strong transforming activity of the Rous sarcoma virus v-Src product in primary chicken embryo ®broblasts, and its potent tumorigenicity in chickens when introduced either by RSV infection or by direct injection of v-src DNA (Fung et al., 1983) . In addition, mutationally activated or overexpressed forms of chicken, mouse, and human cSrc have been shown to transform cells in culture under various conditions (Levy et al., 1986; Tanaka and Fujita, 1986; Lin et al., 1995) , and mutationally activated human c-Src was found to be highly tumorigenic in chickens when introduced with a viral vector (Tanaka et al., 1990) . Taken together, these studies suggested that it was highly likely that aberrant activation of Src kinase activity by mutation or other mechanisms could contribute to the development and progression of some human cancers.
There is a large body of evidence that has demonstrated that Src kinase activity, and sometimes Src protein levels, are elevated in several cancers including colon and breast cancer, with a correlation often observed between increases in Src kinase activity and degree of malignancy (Bolen et al., 1987; Cartwright et al., 1989; Ottenho-Kal et al., 1992; Verbeek et al., 1996; Egan et al., 1999; Biscardi et al., 1999) . As mentioned previously, Src kinase activity can be activated through a number of mechanisms including: (i) binding of Src to activated growth factor receptor tyrosine kinases; (ii) dephosphorylation of the negative regulatory Tyr(527/530) residue by a PTP; and (iii) mutation. Each of these mechanisms could potentially activate Src activity, or in some cases may act in concert with others.
Recently, a c-src mutation that results in an activated, truncated form of human c-Src, that ends with Tyr530, has been identi®ed in highly metastatic forms of colon carcinoma (Irby et al., 1999) . This mutation, which was not detected in less metastatic colon carcinomas, is the ®rst report of an activating Src mutation in human cancer (see review by Yeatman in this issue). Although studies in transfected cells have revealed that the truncated, mutant c-Src protein is phosphorylated in vivo on Tyr530, this protein has elevated kinase activity, presumably because it lacks at least three amino acid residues carboxy-terminal to Tyr530 that are required for proper binding to the SH2 domain and the establishment of an inactive conformation Cantley and Songyang, 1994) . It is very interesting, and perhaps somewhat ®tting, that the ®rst activating mutation of Src to be reported in a human cancer results in a Src protein that is truncated in a location that is similar to that of the v-Src protein of RSV, in a manner that probably abolishes the eectiveness of the carboxyterminal negative regulatory region found in normal cSrc (Irby et al., 1999) .
Conclusions and future directions
Our understanding of Src structure, regulation, localization, and function within the cell has increased dramatically since its ®rst discovery. Numerous modes of Src regulation have now been identi®ed. They include alterations in the phosphorylation status of Src mediated by kinases and phosphatases and/or Src's interaction with Src-binding proteins. Many studies, in particular those that have identi®ed kinases and phosphatases that target Tyr(527/530) of Src, have often utilized overexpression or suppression systems to characterize the regulatory protein's potential role in Src regulation. These studies have been extremely useful in identifying potentially important players in the Src regulation process, although other experiments will be required to address how these factors are utilized normally within the cell to modulate Src kinase activity. Thus, further analyses addressing the regulation of these factors will be critical for the determination of the physiological regulatory processes of Src kinase activation.
It is becoming more evident that Src may be involved in signaling events at various cellular locations. In order to help clarify and elucidate the normal functions of Src and fully comprehend its transforming potential within the cell, Src interactions with speci®c targets or Src-binding proteins at the dierent subcellular locations should be characterized as fully as possible. The speci®c localization of Src to the plasma membrane, cytoskeleton, endosomes, perinuclear membranes and possibly even the nucleus illustrate that Src is a complex signaling molecule with a number of potentially important cellular functions.
Authors note
The present review is not meant to be comprehensive, and will discuss only some of the broad range of topics relevant to Src kinase, especially some topics that have not been discussed extensively in other recent reviews on Src. Several excellent reviews provide substantial coverage of topics not dealt with extensively in this review, such as Src interactions with growth factor receptor tyrosine kinases, and downstream signaling pathways e.g. (Abram and Courtneidge, 2000; Biscardi et al., 1999; Thomas and Brugge, 1997; Taylor and Shalloway, 1996; Brown and Cooper, 1996) . Also, we apologize that because of space limitations, we were not able to cite all relevant references in many instances.
